NMS Moves to Terminate Cardiff's Sole Onvansertib License
Existential License Dispute
Company Background
Cardiff Oncology is a San Diego–based clinical-stage biotechnology company whose entire pipeline rests on a single asset: onvansertib, an oral PLK1 inhibitor being evaluated in RAS-mutated metastatic colorectal cancer. The company has no marketed products and generates only modest royalty income — royalty revenues of $41,000 in the first quarter of 2026 — making it wholly dependent on the clinical and commercial success of onvansertib.
The past eighteen months brought genuine clinical momentum. The Phase 2 CRDF-004 trial achieved a confirmed overall response rate of 72.2% in the 30 mg onvansertib plus FOLFIRI/bevacizumab arm, compared to 43.2% across the combined standard-of-care arms, as of a January 22, 2026 data cut. In April 2026, Cardiff completed an End-of-Phase 2 meeting with the FDA and aligned on design elements for a Phase 3 registrational trial — the most concrete step toward commercialization the company has taken.
That progress came against a backdrop of financial pressure and leadership upheaval. As of March 31, 2026, Cardiff held approximately $46.1 million in cash, cash equivalents, and short-term investments, with management projecting runway only into the first quarter of 2027. In January 2026, both the chief executive and chief financial officer departed simultaneously as part of what the company described as a strategic leadership review, leaving the company under interim and newly installed leadership as it prepares for the most consequential period in its history.
What Was Disclosed
On May 27, 2026, Cardiff received written notice from Nerviano Medical Sciences S.r.l. that NMS was terminating the License Agreement dated March 13, 2017 — the contract under which Cardiff holds rights to develop and commercialize onvansertib. NMS invoked Section 11.3 of the agreement as the basis for termination.
NMS alleges two categories of material breach. The first concerns patent inventorship: NMS claims Cardiff failed to name NMS employee Dr. Barbara Valsasina as a joint inventor on Cardiff's U.S. Patent Nos. 12,144,813 and 12,263,173, and declined to provide NMS a power of attorney to correct inventorship, in breach of Section 10.2(c) of the agreement. The second is a commercialization allegation: NMS further alleges Cardiff failed to use Commercially Reasonable Efforts — as defined in the agreement — to conduct development activities and seek regulatory approvals for onvansertib, in material breach of Sections 7.3, 7.5, and 7.9.
Cardiff promptly responded that the termination notice is legally ineffective, factually unsupported, and procedurally improper, and that it will continue to perform under the agreement. The response represents Cardiff's second formal rejection of NMS's breach claims. Cardiff had first disputed NMS's breach allegation, originally received in February 2026, on the grounds that the agreement does not require it to name NMS employees on inventions made exclusively by Cardiff, and that doing so would require making representations to the U.S. Patent and Trademark Office that Cardiff believes would be false or inaccurate.
Why It Matters
The 2017 NMS license is the legal foundation for everything Cardiff does. Without it, there is no onvansertib program, no Phase 3 trial, and no company in any operational sense. Cardiff has no other clinical-stage assets. The inventorship dispute centers on the two Cardiff patents — U.S. Pat. Nos. 12,144,813 and 12,263,173 — that are also the same patents NMS sought to have corrected under the February 2026 breach notice, meaning the termination is a direct escalation of a dispute that has been building for months.
The timeline is notable for its speed. NMS first raised breach allegations in February 2026. Cardiff filed suit in the U.S. District Court for the Southern District of California on May 19, 2026, seeking injunctive relief requiring NMS to continue performing and a declaratory judgment that Cardiff did not breach the agreement. Eight days later, NMS issued the termination notice. The court proceedings Cardiff initiated are now the primary mechanism for blocking the termination from taking legal effect, and the outcome of that litigation will determine whether Cardiff's Phase 3 plans proceed on any timeline.
The clinical record cuts against NMS's commercially reasonable efforts allegation. Cardiff completed enrollment in the CRDF-004 trial, generated Phase 2 data that led to a successful FDA End-of-Phase 2 meeting in April 2026, and was publicly advancing Phase 3 design details. A net loss of approximately $12.3 million in the first quarter of 2026 reflects active spending on the program. None of that, however, resolves the inventorship question, which turns on contractual interpretation and patent law rather than clinical execution — and which Cardiff and NMS appear to have irreconcilably opposing views on.